Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292371 | 0.98 | PTGS2 (0.44) | PTGS2CYP3A4HTR2ACA2GPR84 | |
| SCHEMBL293925 | 0.94 | SKP2 (0.43) | PTGS2CYP3A4HTR2ACA2GPR84 | |
| SCHEMBL292013 | 0.86 | NPC1 (0.36) | CA2GPR84MAPTRAB9A | |
| SCHEMBL170953 | 0.86 | PTGS2 (0.50) | PTGS2CYP3A4HTR2ACA2GPR84 | |
| SCHEMBL1186069 | 0.84 | PTGS2 (0.52) | PTGS2CYP3A4HTR2AGPR84KDM4E | |
| SCHEMBL1187331 | 0.84 | PTGS2 (0.52) | PTGS2CYP3A4HTR2AGPR84KDM4E | |
| SCHEMBL1186650 | 0.84 | PTGS2 (0.52) | PTGS2CYP3A4HTR2AGPR84KDM4E | |
| SCHEMBL1186516 | 0.84 | PTGS2 (0.52) | PTGS2CYP3A4HTR2AGPR84KDM4E | |
| SCHEMBL829394 | 0.84 | PTGS2 (0.52) | PTGS2CYP3A4HTR2AGPR84KDM4E | |
| SCHEMBL1187072 | 0.84 | PTGS2 (0.52) | PTGS2CYP3A4HTR2AGPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086538-B1 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING DIMEBON AND DONEPEZIL | MEDIVATION NEUROLOGY INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | PTGS2 2497/4885CYP3A4 2379/4885HTR2A 1220/4885 |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | GRIN1, GRIN2A, GRIN3A | PTGS2 676/4885CYP3A4 4335/4885HTR2A 106/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | PTGS2 512/4885CYP3A4 2831/4885HTR2A 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.